consider
progress
made
develop
influenza
antivir
two
major
class
drug
adamantan
neuraminidas
inhibitor
avail
clinic
use
countri
varieti
agent
variou
stage
investig
develop
widescal
use
nai
countri
respons
pandem
provid
much
new
observ
data
effect
oseltamivir
treatment
reduc
risk
sever
influenza
outcom
like
pneumonia
hospit
mortal
hospit
observ
confirm
principl
select
inhibitor
influenza
replic
associ
symptom
relief
complic
reduct
suggest
time
antivir
therapi
respiratori
viral
infect
might
provid
similar
benefit
unfortun
approv
agent
respiratori
virus
use
agent
typic
limit
specif
risk
group
like
infant
immunocompromis
host
one
challeng
develop
vaccin
therapeut
noninfluenza
respiratori
virus
divers
pathogen
repres
six
major
viru
famili
primarili
rna
also
dna
virus
numer
serotyp
genotyp
pathogenesi
infect
rang
broadli
depend
viru
host
clinic
set
mani
ill
remain
uncertain
extent
inhibit
viral
replic
would
associ
clinic
benefit
treatment
data
regard
antivir
noninfluenza
respiratori
virus
deriv
observ
studi
immunocompromis
host
sometim
infant
recent
random
control
trial
specif
target
popul
help
address
potenti
valu
antivir
intervent
follow
commentari
base
present
author
meet
intern
societi
influenza
respiratori
virus
antivir
interest
group
hanoi
novemb
xvth
intern
symposium
respiratori
viral
infect
rotterdam
march
highli
select
review
antivir
treatment
intervent
show
particular
promis
specif
respiratori
virus
focus
primarili
clinic
report
also
includ
observ
preclin
studi
potenti
treatment
lesson
learn
therapeut
studi
sever
acut
respiratori
syndrom
sar
covinfect
patient
sar
patient
role
antivir
therapi
support
find
viral
load
posit
correl
develop
organ
dysfunct
death
sar
character
protract
viru
replic
peak
second
week
ill
promin
host
proinflammatori
respons
histolog
evid
diffus
alveolar
damag
data
regard
viral
replic
pattern
diseas
pathogenesi
current
avail
merscov
infect
although
prolong
viral
replic
lower
respiratori
tract
extrapulmonari
viru
detect
lung
injuri
respiratori
failur
often
renal
failur
notabl
featur
report
case
wide
rang
agent
report
antisarscov
activ
preclin
studi
consider
number
therapeut
intervent
direct
inhibit
cov
replic
modifi
host
respons
infect
attempt
sar
patient
although
corticosteroid
wide
use
treat
progress
sarsrel
pneumonia
effort
reduc
excess
proinflammatori
respons
presum
immunemedi
tissu
damag
benefit
conclus
demonstr
variou
report
document
increas
plasma
viral
load
opportunist
infect
immedi
delay
eg
osteonecrosi
side
effect
addit
systemat
review
observ
report
conclud
common
use
multipl
agent
combin
vari
dose
regimen
pauciti
studi
systemat
data
collect
complic
immunosuppress
therapi
lack
random
control
trial
meant
exist
data
inconclus
regard
put
antivir
thu
inadequ
determin
appropri
manag
sar
infect
use
avail
agent
like
ribavirin
hiv
proteas
inhibitor
associ
proven
benefit
sar
patient
although
retrospect
studi
report
sever
outcom
ard
death
occur
less
often
receiv
combin
lopinavirritonavir
ribavirin
corticosteroid
compar
histor
control
receiv
ribavirin
corticosteroid
earli
combin
treatment
also
associ
fewer
nosocomi
infect
less
use
puls
corticosteroid
progress
diseas
lower
nasopharyng
viral
load
time
perhap
relat
corticosteroidspar
effect
note
mice
high
ribavirin
dose
mgkg
start
hour
prior
sar
viru
exposur
given
twice
daili
day
found
increas
viru
lung
titer
prolong
durat
viru
detect
unclear
whether
ribavirin
might
similar
effect
treat
human
one
small
pediatr
studi
found
correl
ribavirin
administr
plasma
sar
rna
level
sar
patient
ribavirin
associ
also
signific
toxic
includ
hemolyt
anemia
metabol
disturb
like
hypocalcaemia
hypomagnesaemia
one
recent
vitro
studi
found
high
ribavirin
concentr
inhibitori
merscov
vero
cell
combin
recombin
human
lower
concentr
inhibitori
consequ
ribavirin
possibl
role
treat
cov
infect
remain
uncertain
sarscov
impair
induct
interferon
associ
antivir
effect
inhibit
exogen
interferon
cell
cultur
studi
inject
pegyl
highli
protect
given
day
reduc
lung
viral
level
histopatholog
initi
day
postinfect
cynomolgu
macaqu
model
sarscov
hybrid
interferon
interferon
induc
mismatch
doublestrand
poli
c
reduc
lung
viral
titer
murin
model
intranas
applic
interferon
interferon
induc
poli
c
protect
reduc
viru
replic
age
mous
model
sar
interferon
also
immunomodulatori
effect
age
macaqu
model
sar
treatment
type
interferon
reduc
patholog
diminish
proinflammatori
gene
express
includ
level
without
affect
viru
replic
lung
one
observ
canadian
studi
sar
patient
progress
ill
found
synthet
interferon
conjunct
corticosteroid
appear
reduc
time
resolut
pulmonari
infiltr
improv
oxygen
satur
reduc
durat
supplement
oxygen
use
sped
resolut
serum
ldh
elev
compar
corticosteroid
alon
interferon
gener
well
toler
although
associ
transient
reduct
neutrophil
count
elev
transaminas
level
note
merscov
shown
readili
inhibit
type
iii
interferon
human
bronchial
epithelium
ex
vivo
observ
suffici
encourag
support
control
studi
system
interferon
affect
patient
addit
one
approv
agent
select
parasit
infect
oral
nitazoxanid
may
interferoninduc
properti
inhibitori
variou
respiratori
virus
includ
influenza
canin
cov
vitro
shown
promis
doserel
activ
phase
placebocontrol
random
trial
treat
uncompl
influenza
consequ
nitazoxanid
would
interest
agent
test
alon
combin
antivir
cov
infect
protect
efficaci
sarscovneutr
antibodi
includ
human
human
monoclon
direct
spike
protein
demonstr
variou
anim
model
studi
found
potent
antivir
effect
without
evid
immun
enhanc
passiv
immunotherapi
convalesc
plasma
sar
patient
use
treat
sar
patient
advanc
antivir
noninfluenza
rvi
blackwel
publish
ltd
hong
kong
taiwan
openlabel
fashion
appar
clinic
benefit
rapid
decreas
plasma
viral
load
copiesml
undetect
level
hour
infus
among
patient
given
convalesc
plasma
hong
kong
higher
day
hospit
discharg
rate
observ
among
patient
receiv
plasma
day
ill
compar
later
versu
p
among
viral
rtpcr
posit
sarscov
seroneg
compar
seroposit
time
plasma
infus
effort
develop
neutral
human
monoclon
merscov
progress
screen
inhibitor
inhibitor
spike
protein
receptor
interact
describ
exampl
rhesu
macaqu
sar
model
sirna
inhibitor
target
sarscov
genom
proteinand
region
reduc
sarscovinduc
fever
number
infect
cell
histolog
find
diffus
alveolar
damag
compar
control
nonspecif
sirna
given
intranas
prophylaxi
postinfect
preclin
report
suggest
inhibitor
angiotensinconvert
one
attach
site
sar
protein
protein
inhibitor
like
mannosebind
lectin
mbl
might
provid
therapeut
benefit
sar
howev
merscov
use
rather
dipeptidyl
peptidas
initi
infect
much
broader
spectrum
cell
infect
includ
human
swine
bat
cell
sarscov
consequ
inhibitor
would
unlik
exert
specif
inhibit
hcovemc
identif
receptor
use
merscov
may
provid
select
inhibitor
interact
avail
agent
inhibit
enzymat
function
appar
one
studi
sar
patient
found
snp
affect
mbl
express
reduc
level
serum
mbl
compar
control
without
sar
although
serum
mbl
level
correl
diseas
sever
serum
mbl
concentr
vari
wide
due
mutat
promot
code
region
human
mbl
gene
recombin
plasmaderiv
human
mbl
bind
protein
one
nlink
glycosyl
site
inhibit
sarscov
replic
suscept
cell
line
concentr
observ
serum
healthi
individu
cell
entri
inhibitori
effect
appear
mediat
part
block
viral
bind
ctype
lectin
appar
receptor
vivo
therapeut
studi
report
sar
high
dose
recombin
human
mbl
show
activ
lethal
ebola
viru
model
mice
mbl
bind
carbohydr
surfac
wide
rang
respiratori
virus
includ
influenza
paramyxovirus
coronaviru
import
pathogen
mbl
potenti
therapeut
intervent
gener
interest
respiratori
syncyti
viru
wellrecogn
caus
morbid
extrem
age
sever
immunocompromis
condit
mortal
lead
caus
bronchiol
infant
young
children
one
analysi
estim
rsv
infect
associ
approxim
million
episod
acut
lower
respiratori
ill
alri
alri
children
age
year
ill
led
hospit
case
death
global
death
lowand
middleincom
countri
contrast
develop
countri
like
unit
state
rsv
associ
mani
death
adult
age
year
older
children
avail
antivir
option
rsv
quit
limit
much
work
carri
develop
antibodi
prepar
antif
protein
monoclon
palivizumab
current
approv
use
prophylaxi
highrisk
children
effect
reduc
rsvrelat
hospit
high
cost
limit
avail
wellresourc
countri
aerosol
ribavirin
approv
treat
hospit
children
seriou
rsv
ill
use
infrequ
popul
due
difficult
deliveri
method
modest
antivir
clinic
effect
cost
concern
healthcar
worker
exposur
potenti
teratogen
american
academi
pediatr
recommend
routin
use
howev
ribavirin
use
frequent
hematopoiet
stem
cell
transplant
hsct
recipi
high
mortal
risk
rsv
lower
respiratori
tract
ill
lrti
develop
systemat
review
observ
studi
across
multipl
center
found
compar
ribavirin
use
ribavirin
treatment
regardless
rout
whether
combin
immunomodulatori
regimen
intraven
immunoglobulin
ivig
rsv
immunoglobulin
palivizumab
associ
reduc
frequenc
progress
lrti
less
frequent
progress
lrti
significantli
fewer
death
lrti
observ
among
patient
treat
combin
aerosol
ribavirin
immunomodulatori
agent
treat
ribavirin
alon
howev
recent
retrospect
analysi
one
center
experi
conclud
addit
palivizumab
aerosol
ribavirn
improv
outcom
rsvinfect
hsct
recipi
recent
random
control
trial
compar
two
aerosol
ribavirin
regimen
found
intermitt
deliveri
g
hour
everi
hour
appear
effect
prevent
lower
respiratori
progress
standard
continu
one
g
hoursr
easier
administ
data
oral
ribavirin
limit
one
studi
suggest
favor
outcom
hsct
recipi
upper
respiratori
rsv
infect
use
combin
ivig
palivizumab
howev
recent
retrospect
analysi
hematolog
malign
hsct
patient
rsv
paramyxoviru
infect
conclud
oral
ribavirin
clinic
effect
prevent
mortal
lung
transplant
recipi
rsv
human
metapneumoviru
infect
observ
studi
suggest
ribavirin
given
intraven
oral
may
benefici
regard
improv
clinic
outcom
recoveri
lung
function
uncontrol
natur
find
preclud
firm
conclus
control
studi
oral
ribavirin
less
expens
easier
administ
aerosol
ribavirin
warrant
import
patient
group
number
rsv
investig
agent
receiv
degre
recent
clinic
test
although
develop
sever
appar
stop
time
exampl
potent
antif
antibodi
motavizumab
shown
antivir
effect
hospit
children
superior
palivizumab
season
rsv
prophylaxi
atrisk
children
increas
cutan
advers
event
rel
palivizumab
placebocontrol
rct
singl
motavizumab
inject
find
reduct
upper
respiratori
tract
viral
titer
ill
measur
infant
age
month
hospit
rsv
ill
ramilo
et
al
r
present
annual
respiratori
syncyti
viru
symposium
septemb
santa
fe
nm
potent
monoclon
f
protein
develop
among
activ
clinic
develop
polyclon
hightit
rsv
immunoglobulin
adma
biolog
inc
hackensack
nj
usa
test
immunocompromis
patient
prevent
progress
upper
lower
respiratori
tract
ill
topic
appli
f
protein
inhibitor
microdos
therapeutx
monmouth
junction
nj
usa
oral
administ
f
protein
inhibitor
gilead
scienc
inc
foster
citi
ca
usa
result
doubleblind
placebocontrol
studi
test
efficaci
experiment
rsv
infect
adult
volunt
safeti
young
children
hospit
rsv
ill
expect
avail
shortli
envelop
glycoprotein
f
play
import
role
rsv
fusion
entri
host
cell
serv
attract
target
develop
rsv
entri
inhibitor
although
resist
emerg
notabl
limit
earlier
studi
agent
progress
furthest
test
doublestrand
oligonucleotid
direct
viral
n
gene
alnylam
pharmaceut
cambridg
usa
sirna
complementari
mrna
encod
n
protein
show
robust
antivir
effect
vitro
murin
model
reduct
lung
viru
titer
activ
given
intranas
volunt
experiment
infect
rsv
placebocontrol
rct
lung
transplant
recipi
rsv
infect
aerosol
mgkg
given
daili
day
gener
well
toler
significantli
reduc
risk
new
progress
bronchiol
obliteran
syndrom
bo
day
compar
placebo
versu
differ
upper
respiratori
tract
viral
load
lower
could
test
consequ
larger
phase
rct
conduct
site
six
countri
dose
extend
day
administr
ad
standard
care
primari
endpoint
bo
day
among
lung
transplant
patient
intenttotreatinfect
popul
tend
lower
inhal
versu
p
significantli
lower
among
patient
perprotocol
analysi
versu
death
occur
placebo
sirna
recipi
unrel
treatment
encourag
result
warrant
studi
novel
sirna
therapeut
risk
popul
support
studi
sirna
inhibitor
respiratori
viral
infect
parainfluenza
viru
piv
ill
sever
immunocompromis
host
particularli
hsct
recipi
result
ribavirin
quit
mix
aerosol
ribavirin
result
reduct
viral
shed
surviv
benefit
hsct
piv
pneumonia
oral
intraven
ribavirin
provid
appar
benefit
individu
hsct
recipi
hematolog
malign
patient
piv
ill
recent
retrospect
analysi
conclud
oral
ribavirin
reduc
mortal
hematolog
malign
patient
paramyxoviru
infect
compar
support
care
alon
wherea
oral
ribavirin
seem
associ
benefit
lung
transplant
patient
paramyxoviru
infect
new
investig
agent
sever
piv
infect
fusion
construct
includ
sialidas
actinomycosi
viscosu
cleav
sialic
acid
receptor
host
cell
consequ
antivir
spectrum
includ
influenza
virus
activ
topic
appli
anim
influenza
model
includ
avian
virus
shown
antivir
effect
phase
rct
uncompl
human
influenza
note
hn
protein
piv
also
bind
sialic
acid
receptor
inhibitori
piv
cell
cultur
human
airway
epithelium
given
intranas
cotton
rat
model
administ
compassion
use
basi
treat
hsct
lung
transplant
patient
sever
piv
ill
appar
clinic
benefit
antivir
effect
case
hostdirect
agent
avail
compassion
use
sponsor
formerli
nexbio
ansun
biopharma
inc
san
diego
advanc
antivir
noninfluenza
rvi
blackwel
publish
ltd
ca
usa
openlabel
studi
undertaken
nih
particular
problem
adenoviru
infect
often
sever
immunocompromis
host
occasion
commun
well
current
approv
antivir
adenoviru
treatment
number
agent
degre
vitro
inhibitori
activ
ribavirin
variabl
vitro
activ
high
concentr
proven
larg
ineffect
treatment
seriou
infect
intraven
cidofovir
nucleosid
phosphon
analog
becom
standard
treatment
immunocompromis
patient
adenoviru
diseas
use
associ
nephrotox
neutropenia
patient
donor
leukocyt
infus
use
vitroexpand
adenovirusspecif
cell
use
patient
promis
antiadenoviru
antivir
clinic
develop
oral
administ
lipid
ester
deriv
cidofovir
design
brincidofovir
chimerix
durham
nc
usa
vitro
provid
higher
intracellular
level
compar
parent
molecul
activ
cidofovir
adenovirus
shown
inhibitori
lethal
adenoviru
infect
syrian
hamster
model
addit
advantag
oral
bioavail
also
lower
risk
nephrotox
compar
cidofovir
clinic
use
one
case
seri
immunocompromis
patient
major
hsct
recipi
describ
use
sever
adenoviru
diseas
adenoviremia
six
dissemin
diseas
involv
organ
follow
onset
adenovir
diseas
median
day
posttranspl
initi
treat
cidofovir
switch
either
persist
viral
replic
nephrotox
prolong
cours
associ
good
virolog
respons
includ
least
reduct
plasma
adenovir
dna
level
nine
patient
delay
mortal
also
observ
among
virolog
respons
two
current
studi
provid
insight
regard
clinic
util
adenovir
infect
highrisk
popul
one
control
trial
preemptiv
therapi
hsct
patient
adenoviremia
finish
enrol
analysi
openlabel
studi
treat
varieti
seriou
dna
viral
diseas
includ
due
adenovirus
immunocompromis
host
initi
press
releas
august
indciat
mg
biw
decreas
level
adenoviremia
show
potenti
benefit
reduc
progress
adenoviru
diseas
allcaus
mortal
compar
subject
receiv
placebo
given
weekli
phase
safeti
pharmacolog
studi
complet
healthi
volunt
promis
agent
also
warrant
test
nonimmunocompromis
host
sever
adenoviru
ill
human
rhinoviru
hrv
infect
frequent
infect
human
experi
implic
caus
wide
rang
respiratori
tract
syndrom
addit
frequent
caus
cold
hrv
infect
lead
caus
exacerb
asthma
chronic
obstruct
pulmonari
diseas
past
studi
capsidbind
antihrv
agent
pleconaril
show
earli
treatment
exert
antivir
effect
reduc
durat
uncompl
hrv
cold
day
symptomat
improv
pleconariltr
subject
relat
drug
suscept
infect
hrv
strain
reduc
suscept
emerg
recipi
howev
approv
clinic
use
larg
potenti
drug
interact
concern
recent
anoth
capsidbind
antihrv
agent
design
vapendavir
biota
hold
ltd
not
hill
vic
australia
show
doserel
antivir
effect
experiment
infect
volunt
benefici
effect
phase
placebocontrol
rct
asthmat
cold
symptom
among
person
enrol
document
hrv
infect
oral
vapendavir
mg
twice
daili
day
associ
significantli
lower
upper
respiratori
symptom
score
earli
ill
continu
week
compar
placebo
vapendavir
recipi
also
signific
improv
secondari
outcom
includ
higher
peak
expiratori
flow
rate
day
reduc
overal
use
asthma
relief
medic
less
frequent
hrv
rna
detect
day
versu
modest
degre
antivir
effect
rais
possibl
potent
inhibit
might
abl
provid
even
greater
clinic
benefit
intranas
recombin
shown
effect
prevent
hrv
cold
use
postexposur
prophylaxi
ineffect
treatment
establish
cold
also
associ
local
side
effect
recent
day
treatment
inhal
interferonbeta
design
synairgen
plc
southampton
england
associ
therapeut
efficaci
phase
placebocontrol
rct
adult
asthmat
receiv
inhal
corticosteroid
histori
deterior
cold
among
enrol
met
criteria
cold
hrv
repres
respiratori
virus
detect
although
trial
meet
primari
endpoint
chang
shorten
asthma
control
questionnair
overal
popul
among
subset
difficult
treat
asthma
patient
repres
onehalf
enrol
inhal
associ
signific
improv
asthma
symptom
fewer
moder
exacerb
improv
morn
peak
expiratori
flow
rate
reduc
use
relief
bronchodil
find
oral
vapendavir
inhal
interferonbeta
studi
need
confirm
larger
trial
result
suggest
earli
antivir
treatment
cold
asthmat
moder
asthma
exacerb
summari
current
mani
unmet
medic
need
approv
agent
noninfluenza
respiratori
viru
infect
recent
studi
provid
encourag
result
seriou
respiratori
viral
infect
hospit
immunocompromis
host
outpati
asthmat
cold
addit
trial
need
confirm
efficaci
safeti
agent
discuss
select
antivir
offer
opportun
expand
therapeut
studi
patient
popul
one
challeng
develop
effect
therapeut
divers
respiratori
virus
differ
diseas
pathogenesi
across
virus
patient
group
addit
piv
sever
agent
clinic
develop
influenza
eg
favipiravir
nitazoxanid
vitro
activ
sever
respiratori
virus
addit
analog
work
influenza
one
forwardlook
strategi
understand
respiratori
virus
interact
host
cellular
pathway
replic
identifi
potenti
viralhost
protein
interact
target
exampl
one
larg
mrna
gene
express
databas
search
identifi
common
pathway
among
seven
differ
respiratori
virus
top
five
pathway
differenti
express
gene
affect
least
five
seven
virus
studi
might
lead
identifi
exist
drug
could
repurpos
target
pathway
eventu
broader
spectrum
antivir
agent
